Financial Contrast: Black Titan (BTTC) and Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it compare to its competitors? We will compare Black Titan to similar businesses based on the strength of its risk, analyst recommendations, earnings, dividends, valuation, institutional ownership and profitability.

Profitability

This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.08%	-912.69%	-63.05%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Black Titan and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	98	197	218	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 108.12%. Given Black Titan’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

57.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Black Titan and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.62
Black Titan Competitors	$223.24 million	-$53.25 million	-11.04

Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Black Titan has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.68, meaning that their average share price is 32% less volatile than the S&P 500.

Summary

Black Titan competitors beat Black Titan on 7 of the 12 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.